Psychedelics IP Protection: Cybin Nabs US Patent For Deuterated Analogs, Psilera Advances Next-Gen Library

Cybin’s New US Patent Covers Proprietary Deuterated Psychedelic Analogs

Clinical-stage biotech company Cybin Inc. CYBN received a U.S. patent covering composition of matter claims for deuterated tryptamines, including the novel psilocybin analog in the company’s CYB003 investigational program and novel DMT analog in its CYB004 program, as well as additional preclinical programs. 

The patent is expected to provide exclusivity until 2041, and also covers claims around methods of treating Major Depressive Disorder (MDD) -see CYB003’s Phase 2 trial on MDD participants- and Treatment-Resistant Depression (TRD.)

CYB004 is a novel deuterated DMT program targeting the treatment of Generalized Anxiety Disorder (GAD) with dosing currently underway is a three-part Phase 1 clinical study.

Both Phase 2 and Phase 1 trials would offer topline data within the third and fourth quarters of 2023.

CEO Doug Drysdale says the team is pleased with the composition of the patent, especially as it supports CYB003 program’s further clinical development. “With this patent granted, we move forward with conviction in our mission of bringing novel, improved treatment options to people suffering from anxiety and depression.”

See Also: Cybin's Q1 2023 Financials, Deuterated Psychedelics Moving 'Steadily' Through The Clinic

Psilera Receives Allowance On ‘Flagship Patent’ On Take-Home Novel Compounds Library 

Private biopharma company Psilera Inc. has received a USPTO notice of allowance for its filed patent application around novel compositions of matter and pharmaceutical compositions.

The new notice “bolsters” Psilera's IP portfolio, composed of several novel, psychoactive natural products-based serotonergic drugs that would provide rapid therapeutic benefit and fewer side effects than conventional treatments on a potential take-home basis for psychiatric, addiction, and neurodegenerative disorders. 

Its proprietary drug discovery engine, Psilera Third Eye, combines novel syntheses of new compounds with an AI-enabled screening platform to design next-generation neurological drugs at the atomic level.

"This landmark development represents one of the most significant IP allowances of a next-generation psychedelic compound library to date," said CEO Dr. Chris Witowski. "Securing this patent is not just a legal milestone; it's a testament to our relentless pursuit of innovation and our commitment to shaping a brighter future for patients with unmet needs."

The allowance marks Psilera's second patent milestone following the issuance of formulations covering DMT and psilocybin-like prodrug psilacetin.

Curious about what’s going on in other natural-based markets? Then Benzinga’s Cannabis Capital Conference is the place to be.

This Sept. 27-28 come join us in Chicago for two days of a fun and immersive environment. It’s our 17th edition, so we kind of know our way around the industry. Get your tickets today and be at the core of cannabis investment and branding!

Photo: Benzinga edit with photo by Photon photo and Jynto on Wikimedia Commons.